Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Pancreatic Diseases"
Show Display Options
Rank Status Study
1 Recruiting A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Condition: Resectable Pancreatic Cancer
Intervention: Drug: LDE-225
2 Recruiting Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
Condition: Stage IV Pancreatic Cancer
Interventions: Drug: nab-paclitaxel;   Drug: Cisplatin;   Drug: gemcitabine
3 Recruiting A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Condition: Pancreatic Cancer, Adult
Interventions: Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: NPC-1C
4 Recruiting Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Conditions: Metastatic Pancreatic Cancer;   Metastatic Colorectal Cancer
Intervention: Drug: NPC-1C/NEO-102

Indicates status has not been verified in more than two years